
    
      This is a Phase 2, multicentre, multinational, randomised, double-blind, placebo-controlled
      study to evaluate the efficacy and safety of two intravenous (IV) treatment regimens of
      anifrolumab versus placebo while taking standard of care (SOC) treatment with mycophenolate
      mofetil (MMF) and corticosteroids in adult subjects with active proliferative lupus nephritis
      (LN).
    
  